The upfront cash portion of the consideration represents a premium of 274% to Regulus’ 60-day volume-weighted average stock price and 108% to Regulus’ closing price on April 29, 2025.

Regulus is a clinical-stage biopharmaceutical company developing microRNA therapeutics for severe renal disease and autosomal dominant polycystic kidney disease (ADPKD).

Also Read: Novartis Q1 Earnings Beat Street View, CEO ‘Confident’ In Delivering Upgraded Guidance

The lead asset for ADPKD, farabursen, is a novel, next-generation oligonucleotide targeting miR-17 that recently completed a Phase 1b multiple-ascending dose clinical trial.

In addition, Regulus shareholders will receive a contingent value right (CVR) providing for payment of $7.00 per share, contingent upon the achievement of a milestone regarding the regulatory approval of Regulus’ lead product candidate, farabursen.

If the milestone is achieved, total consideration, including the CVR, would be approximately $1.7 billion.

The transaction is expected to close in the second half of 2025. Regulus will continue to operate as a separate and independent company.

In March, Regulus Therapeutics released topline results from all patients in the fourth cohort in its Phase 1b MAD study of farabursen (RGLS8429) for ADPKD.

Cohort 4 data highlights:

Price Action: RGLS stock is up 132.9% at $7.85 during the premarket session at the last check Wednesday.

Read Next:

• Analyst Says Trade Desk Can Shake Off Challenges, Ride Streaming’s Next Big Wav

Photo: Shutterstock